Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACXP | US
-0.10
-6.90%
Healthcare
Biotechnology
30/06/2024
06/03/2026
1.35
1.45
1.47
1.33
Acurx Pharmaceuticals Inc. a clinical stage biopharmaceutical company develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C a potential oral and parenteral treatment targeting gram-positive bacteria including methicillin-resistant staphylococcus aureus vancomycin-resistant enterococcus and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island New York.
View LessNegative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
78.8%1 month
70.0%3 months
105.7%6 months
157.6%-
-
9.57
-
-
-3.54
-
-
-
21.93M
21.93M
-
-
-
-
-346.94
8.41
3.55
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.59
Range1M
1.03
Range3M
3.27
Rel. volume
1.20
Price X volume
86.51K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| iBio Inc | IBIO | Biotechnology | 2.61 | 23.85M | -1.14% | n/a | 20.92% |
| Xilio Therapeutics Inc. Common Stock | XLO | Biotechnology | 0.53 | 23.29M | -2.11% | n/a | 25.98% |
| Dyadic International Inc | DYAI | Biotechnology | 0.7676 | 22.63M | 0.99% | n/a | 175.64% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 6.98 | 22.31M | 4.80% | n/a | 14.63% |
| Edesa Biotech Inc | EDSA | Biotechnology | 6.52 | 21.17M | 80.61% | n/a | 1.35% |
| JSPR | JSPR | Biotechnology | 1.38 | 20.85M | 0.73% | n/a | 2.31% |
| IO Biotech Inc. Common Stock | IOBT | Biotechnology | 0.3005 | 19.80M | -7.77% | n/a | 2.23% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 6.43 | 19.57M | -1.98% | n/a | 10.72% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.7902 | 18.95M | -5.98% | n/a | 0.00% |
| Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.85 | 18.86M | -2.63% | n/a | 2.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6345 | 12.26M | -10.63% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 4.16 | 6.34M | 6.67% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.4799 | 3.78M | -0.68% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.397 | 3.78M | -1.73% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.39 | 1.32M | -3.24% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.54 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 9.57 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 105.71 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 21.93M | 3.66B | Emerging |